• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

As the fourth quarter (December-ending) results announcement of Aventis Pharma draws near, Dalal Street's attention has turned to its rising earning prospects. The stock closed at Rs 1424.70 (up over 1.5 per cent on Wednesday and 3 per cent in the past one week) indicating beginning of a northward journey and the traded quantity (1.02 lakh shares on the NSE) also suggested activity.

The expected EPS for 2006 is Rs 90 (against the previous year EPS of Rs 63) without taking into account earning of its subsidiary Roussel India.

Market players are also expecting a stock split followed by a bonus issue.

Jayanta Mallick

More Stories on : Stock Markets | Stocks | Ear to the ground | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Anti-cyclone seen affecting easterly wave

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line